CN105816469B

CN105816469B - Application of 20(R) -ginsenoside Rg3 in preparation of medicine or health product for treating osteoporosis and medicine

Info

Publication number: CN105816469B
Application number: CN201510005661.8A
Authority: CN
Inventors: 富力; 刘正贤; 鲁明明; 王凯乾; 惠敏; 鲁岐; 王硕; 柳洋; 冯雪; 盖鑫; 付强; 付文斐; 周庆丰
Original assignee: Individual
Current assignee: Individual
Priority date: 2015-01-06
Filing date: 2015-01-06
Publication date: 2020-06-26
Anticipated expiration: 2035-01-06
Also published as: WO2016110167A1; CN105816469A

Abstract

The invention discloses a new application of 20(R) -ginsenoside Rg3 in preparing a medicament for treating osteoporosis. Experiments prove that the 20(R) -ginsenoside Rg3 has obvious curative effect on osteoporosis, quick response and small toxic and side effects, is a medicine for treating osteoporosis, is safe, efficient, stable and simple in preparation process, is suitable for industrial production and is easy to popularize. The invention provides a new medicine source for treating osteoporosis.

Description

Application of 20(R) -ginsenoside Rg3 in preparation of medicine or health product for treating osteoporosis and medicine

Technical Field

The invention belongs to the field of medicines, relates to a medicine or health-care food for treating osteoporosis, and particularly relates to application of a traditional Chinese medicine ginseng extract in the medicine or health-care food for treating osteoporosis.

Background

Osteoporosis is mainly classified into primary and secondary types, the primary type is classified into type I and type II except idiopathic type, the type I is also called postmenopausal osteoporosis and is a high-conversion type, and the main reason is estrogen deficiency; type II is also known as senile osteoporosis, and is a low turnover type due to aging. Osteoporosis is caused by various factors, and the basic pathological mechanism of the osteoporosis is that the coupling of bone absorption and bone formation in the bone metabolic process is defective, so that the calcium and phosphorus metabolism in a human body is unbalanced, and the bone density is gradually reduced to cause clinical symptoms.

The most common symptoms of primary osteoporosis, including backache, account for 70-80% of pain patients. Pain spreads laterally along the spine, is relieved when lying on the back or sitting, is aggravated when standing upright or standing long or sitting, is mild in daytime, is aggravated when waking up at night or in the early morning, and is aggravated when stooping, muscle exercise, cough and stool are forcefully applied. Generally, bone pain occurs when more than 12% of the bone mass is lost. In senile osteoporosis, vertebral body bone trabecula atrophy, the number is reduced, vertebral body compression deformation, spine anteflexion, waist rash muscle, double contraction, muscle fatigue and even spasm generate pain in order to correct spine anteflexion. More recently, the compression fracture of the thoracolumbar spine can also cause acute pain, the spinous process of the spine at the corresponding part can have strong pressure pain and percussion pain, which can be gradually relieved after 2-3 weeks, and some patients can have chronic lumbago. If the corresponding spinal nerves are pressed, the limb radiation pain, the sensory and motor disturbance of both lower limbs, the intercostal neuralgia and the pain after the sternum can be caused to be similar to angina pectoris, and the epigastric pain can also be similar to acute abdomen. If the pressure is applied to the spinal cord and cauda equina, the function of the bladder and rectum is affected. Most of them appear after pain. The front part of the vertebral body of the vertebra almost consists of cancellous bones, the part is a support column of the body, the load is heavy, particularly the 11 th thoracic vertebra, the 12 th thoracic vertebra and the 3 rd lumbar vertebra, the load is larger, the vertebral body is easy to compress and deform, the vertebra is inclined forwards, the dorsiflexion is aggravated to form the kyphosis, the osteoporosis is aggravated along with the age increase, the kyphosis curvature is increased, and the contracture of the knee joint is caused to be remarkable. Each person has 24 sections of centrum, the height of each centrum of normal people is about 2cm, the centrum is compressed when the bone of the old people is loose, each centrum is shortened by about 2mm, and the length of the body is shortened by 3-6 cm on average. Compression fracture of thoracic and lumbar vertebrae, retroversion of spine, and thoracic deformity can significantly reduce vital capacity and maximum ventilation volume, and symptoms such as chest distress, short breath, dyspnea, etc. often appear in patients.

The diagnosis of postmenopausal and senile osteoporosis is to exclude secondary osteoporosis caused by various other reasons, such as hyperparathyroidism and multiple myeloma, osteomalacia, renal osteodystrophy, osteogenesis imperfecta in children, metastasis, leukemia, lymphoma, etc.

And (3) carrying out graded diagnosis on osteoporosis: normal is BMD or BMC within 1 Standard Deviation (SD) of the mean of normal adult bone density; the osteopenia is that BMD or BMC is reduced by 1-2.5 standard deviations compared with the average value of bone density of normal adults; the osteoporosis is that BMD or BMC is reduced by more than 2.5 standard deviations compared with the average value of normal adult bone density; severe osteoporosis is a reduction in BMD or BMC by more than 2.5 standard deviations from the mean value of normal adult bone density with 1 or more than 1 brittle fracture. BMD or BMC in the diagnostic criteria may be determined in the central or peripheral bone.

The medicines for preventing and treating osteoporosis clinically comprise calcium preparations including Yidele, Kaisili, Caliqi D, Leli, calcium gluconate oral liquid, Longchang calcium + D oral liquid, jindeca, megaenergy calcium and ultramicro calcium, medicines for inhibiting bone absorption, such as dehydrogesterone, Beimeili tablet and Liweiai, bisphosphonates, such as Fujimeimei, Gulin, Bandein and Jilisuning, osteogenesis treatment medicines, such as tylidine, and vitamin medicines for promoting mineralization, such as Fanen (l α -hydroxy vitamin D3), Rogocrine (calcitriol), Gewang (alfacalcidol) and Liqing (alfacalcidol tablet).

Only after the fracture occurs due to osteoporosis, surgical treatment is required, which aims to treat the fracture and restore the normal function as early as possible.

Modern medical research shows that the main effects and functions of ginseng are as follows: has effects in resisting cancer and tumor, regulating immunity, resisting diabetes, improving liver function, relieving cardiovascular and cerebrovascular disorders, resisting arteriosclerosis, regulating blood pressure, relieving climacteric disorder and osteoporosis, relieving fatigue, resisting oxidation, and inhibiting aging. Ginsenoside has been widely studied and used as a main active ingredient of ginseng, and among them, 20(R) -ginsenoside Rg3 is most spotlighted, and it has good safety as a main active ingredient of ginseng, has been prepared into an anti-tumor oral preparation for clinical use, and has been intensively studied as an injection.

The inventor extracts the effective component 20(R) -ginsenoside Rg3 for treating osteoporosis from ginseng medicinal materials by adopting an advanced separation and purification technology through a large amount of modern scientific researches, and performs pharmacodynamic and pharmacological researches on 20(R) -ginsenoside Rg3 and corresponding medicinal preparations thereof for treating osteoporosis, and the results show that the 20(R) -ginsenoside Rg3 monomer has clear pharmacological action, strong effect on treating osteoporosis, low toxic and side effects and high safety, and can provide a high-efficiency and low-toxicity medicine for treating osteoporosis.

Disclosure of Invention

The invention aims at solving the technical problems of the existing medicines or health-care products for treating osteoporosis, provides the performance and efficacy of treating osteoporosis by using 20(R) -ginsenoside Rg3, and provides a new medicinal application of 20(R) -ginsenoside Rg3, namely a new application in medicines or health-care products for treating osteoporosis.

In order to realize the purpose of the invention, the invention provides the application of the 20(R) -ginsenoside Rg3 in preparing the medicines or health products for treating osteoporosis.

In the process of screening natural active ingredients with the effect of treating osteoporosis, the inventor finds that 20(R) -ginsenoside Rg3 in the chemical ingredients of ginseng has a strong effect of treating osteoporosis.

Wherein, the medicine or the health care product consists of 20(R) -ginsenoside Rg3 and a pharmaceutically acceptable carrier.

Wherein, the content of the 20(R) -ginsenoside Rg3 is more than or equal to 1 percent, preferably more than or equal to 30 percent, more preferably more than or equal to 60 percent, even more preferably more than or equal to 80 percent, even more preferably more than or equal to 98 percent.

Particularly, the content of the 20(R) -ginsenoside Rg3 is 1 to 98 percent; preferably 30 to 80%, and more preferably 60%.

In particular, pharmaceutically acceptable carriers are generally approved by health care professionals for this purpose and as inactive ingredients of medicaments. A compilation of pharmaceutically acceptable carriers can be found in tools such as Handbook of Pharmaceutical excipients (2 nd edition, edited by A.Wade and P.J.Weller; published by American Pharmaceutical Association, Washington and The Pharmaceutical Press, London, 1994).

In particular, the carrier includes excipients such as starch, water, and the like; lubricants, such as magnesium stearate and the like; disintegrants, such as microcrystalline cellulose and the like; fillers, such as lactose and the like; binders such as pregelatinized starch, dextrin, and the like; a sweetener; an antioxidant; preservatives, flavoring agents, spices, and the like.

Wherein the medicament is in the form of tablets, capsules, pills, powders, granules, syrups, solutions, emulsions, injections, sprays, aerosols, gels, creams, tinctures, cataplasms, rubber plasters or plasters.

In particular, the content of the 20(R) -ginsenoside Rg3 is more than or equal to 1 percent, preferably more than or equal to 30 percent, more preferably more than or equal to 60 percent, even more preferably more than or equal to 80 percent, and even more preferably more than or equal to 98 percent.

In another aspect, the invention provides a medicament or health product containing 20(R) -ginsenoside Rg3 for treating osteoporosis.

Particularly, the content of the 20(R) -ginsenoside Rg3 is preferably 1-98%; more preferably 30 to 80%, and still more preferably 60%.

Particularly, the ratio of the weight of the 20(R) -ginsenoside Rg3 to the total weight of the medicine or health care product is 0.01-10: 100, preferably 0.1 to 10: 100, more preferably 1 to 10: 100.

in particular, the medicine or the health care product also comprises one or more of astragalus extract, salvia extract, epimedium extract, dogwood extract, liquorice extract, black sesame extract, ginger extract, grape seed extract, pomegranate seed extract, plant essential oil, arbutin, vitamin C and derivatives thereof or vitamin E and derivatives thereof.

The medicine can be made into various dosage forms by methods known in the art, such as tablets, capsules, pills, powders, granules, syrups, solutions, injections, sprays, aerosols, gel types, creams, tinctures, cataplasms, rubber plasters or emplastrums, and the like.

The invention also provides a method for treating osteoporosis, which comprises the step of administering a therapeutically effective amount of the pharmaceutical composition of 20(R) -ginsenoside Rg3 to a subject, wherein the therapeutically effective amount is 0.6-12 mg/kg d, preferably 1-6 mg/kg d, and further preferably 1.5-3 mg/kg d.

As used herein, unless otherwise indicated, the term "therapeutically effective amount" is the amount of a drug required to produce an effective effect; the "therapeutically effective amount" is adjustable and variable and ultimately determined by the medical practitioner, taking into account factors including the route of administration and the nature of the formulation, the general condition of the recipient's weight, age, etc., and the nature and severity of the condition being treated.

Compared with the prior art, the invention has the following obvious advantages:

1. the invention develops new medicinal value for the known compound 20(R) -ginsenoside Rg3, and the compound can be used for preventing and treating osteoporosis and can be prepared into medicaments or health-care food for treating the osteoporosis, thereby developing a new field for the application of ginseng medicinal materials.

2. Series of experimental studies prove that the 20(R) -ginsenoside Rg3 has obvious effect of treating osteoporosis.

3. The 20(R) -ginsenoside Rg3 has strong pharmacological action, obvious effect of treating osteoporosis, quick response, small toxic and side effect and good safety, can be taken for a long time, and has good medicinal prospect.

4. The product of the invention has rich raw material sources, low price, safe clinical use, simple preparation process, small dosage and convenient use, can be prepared into various dosage forms, and is easy to popularize.

5. The compound medicine for treating osteoporosis can be prepared by adopting a single-component 20(R) -ginsenoside Rg3 active component, and can also be prepared by adopting a common formula of the 20(R) -ginsenoside Rg3 and other active components (such as astragalus membranaceus, salvia miltiorrhiza, epimedium herb, dogwood, liquorice, black sesame extract, ginger extract, grape seed extract, pomegranate seed extract, plant essential oil, arbutin, vitamin C and derivatives thereof or vitamin E and derivatives thereof).

Detailed description of the preferred embodiments

The benefits of the formulations of the present invention are further described below in the detailed description. These examples are merely illustrative and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims

The experimental procedures, for which specific experimental conditions are not indicated in the following examples, are generally carried out according to conventional conditions, or according to conditions recommended by the manufacturers. The beneficial effects of the drug of the present invention are further illustrated by the following test examples, which include pharmacodynamic tests of the drug of the present invention.

Example 1Rg3 tablet

1. The raw materials are prepared according to the following mixture ratio

Mixing ginsenoside Rg3 and starch, granulating, adding pulvis Talci and magnesium stearate, mixing, and tabletting.

Example 2Rg3 Capsule

1. The raw materials are prepared according to the following mixture ratio

Ginsenoside Rg3 (content 63%) 200g

Starch 1000g

Mixing ginsenoside Rg3 and starch, and making into capsule with a size of 10000.

Example 3Rg3 granules

1. The raw materials are prepared according to the following mixture ratio

Ginsenoside Rg3 (content 98%) 10g

Microcrystalline cellulose 1000g

Mixing ginsenoside Rg3 and microcrystalline cellulose, granulating, bagging, and making into 10000 bags.

Example 4Rg3 tablet

1. The raw materials are prepared according to the following mixture ratio

Mixing ginsenoside rg3, Glycyrrhrizae radix extract, vitamin C and starch, granulating, adding pulvis Talci and magnesium stearate, mixing, and pressing into 10000 tablets.

Example 5 Rg3 Capsule

Mixing ginsenoside Rg3, radix astragali extract, vitamin C and starch, and making into capsule with a dosage of 10000 granules.

Example 6 Rg3 granules

Mixing ginsenoside Rg3, Corni fructus extract, vitamin C and sucrose powder, granulating, and packaging into 10000 bags.

Example 7 Rg3 oral liquid

1. The raw materials are prepared according to the following mixture ratio

Dissolving ginsenoside Rg3 with small amount of ethanol, adding Saviae Miltiorrhizae radix extract, semen Sesami Niger extract and glucose syrup, and adding deionized water to 100 ml.

Experimental example 120 (R) -ginsenoside Rg3 pharmacodynamic experiment for resisting osteoporosis

1 materials of the experiment

1.1 drugs and reagents

20(R) -ginsenoside Rg3, provided by the research laboratory of pharmaceutical preparations of Dalian Fusheng Natural drug development Co., Ltd., batch number: 2012303, respectively; using the ginsenoside Rg3 standard substance provided by Chinese medicine biological product verification for reference and performing HPLC calibration, wherein the content is 98.2%;

positive control drug: nilestriol tablets are manufactured by Beijing tetracyclic pharmaceuticals, Inc., national drug Standard Hl1020123, lmg/tablet, 10 tablets/box. Before use, the mixture is ground into fine powder in a bowl and suspended by 0.5 percent CMC-Na to prepare 0.05mg/m1 suspension;

negative control drugs: physiological saline, provided by Ningxia Shuiyuan national drug Co., Ltd, lot number member 100221-1;

anesthetic drugs: 10% chloral hydrate;

the other reagents are analytically pure.

1.2 Experimental animals

Wistar female rats of 8 months of age, the body weight of 220- & gt 310g, purchased from the experimental animal center of Dalian medical university, the quality certification number: SCXK (13) 2012-.

1.3 Experimental instruments

BIO-RAD type plate washer, Model-680 type enzyme marker, DHP-9082 type electric heating constant temperature incubator, Olympus AU2700 full-automatic biochemical analyzer, TD5A-WS desk type low speed centrifuge, etc. are provided by Ningxia medical university.

2 method of experiment

2.1 Molding method

Ovariectomized model mice: 30mg/kg of 10% chloral hydrate is anesthetized by intraperitoneal injection, strict aseptic operation is performed, a middle incision of the abdomen is taken, the abdominal cavity is filled, the ovaries on two sides are completely removed, after complete hemostasis is achieved, muscles and skin are sutured in sequence in two layers, and the removed ovaries are all confirmed by pathology: the incision of the sham operation group is the same as that of the sham operation group, the left mesentery and the right mesentery are cut off after entering the abdominal cavity, the ovaries on both sides are taken out and placed in vitro after lmin is placed, the weight of the ovaries is basically the same as that of the ovaries on both sides, the ovaries are not removed, and the hemostatic suture is carried out. The wound is sprinkled with penicillin powder, and the wound is free from infection after operation and healed according to the period. Continuous vaginal smears were not periodically changed 5 days after ovariectomy, and the uterus was atrophied at necropsy.

2.2 animal grouping and administration methods

After modeling, 48 Wistar rats are divided into 6 groups including an RG3 high dose group (short for a high dose group), an RG3 medium dose group (short for a medium dose group), an RG3 low dose group (short for a low dose group), a positive control group, a model blank group and a pseudo-operation group according to weight layers, wherein each group comprises 8 rats which are all administrated in the second half month after operation. The model group was subjected to a saline intragastric administration of 2ml/kg body weight once a day for 12 weeks, and the sham operation group was treated with the same model group. The RG3 high, medium and low dose groups were administered at 6mg/kg, 3mg/kg and 1.5mg/kg, respectively. Once daily for 12 weeks. The positive control group was gavaged with nilestriol 0.15mg/kg once a week, and then with distilled water 6 times a week for 12 weeks, 2 ml/kg. The food intake is controlled by freely drinking water and taking the food for 12 weeks in the same environment.

After the drug intervention for 12 weeks and months, after the last administration, each group of animals were anesthetized by intraperitoneal injection of 10% chloral hydrate (30ml/kg), and then placed in a prone position in a dual-energy X-ray bone density diagnostic apparatus, and the 1 st to 5 th lumbar vertebrae and femurs of rats were scanned in a high resolution mode by using small animal measurement software, wherein the scanning parameters were as follows: l.0xl.0mm, 60mm/s, 12.00cm REV3.9.3/2.1.0, precision of 1.5% and accuracy of 90%.

3 results of the experiment

The results of bone density measurements of rats in each group were compared by one-way anova, and between groups, by SNK-q, at a test level of α of 0.05, with the results shown in table 1.

TABLE 1 Effect of RG3 on bone Density in castrated females (x. + -. s n ═ 8)

Note: comparison with model group: p <0.01, x: p < 0.001.

From the experimental results of table 1, it can be seen that: compared with the sham operation group, the bone density of the thighbone, the lumbar vertebrae and the whole body is obviously reduced (p is less than 0.01), which shows that the bone mineral content of the ovariectomized female mouse is obviously reduced; compared with the model group, the RG3 high and medium dose group remarkably improves the bone density (p is less than 0.01, p is less than 0.001) of the corresponding part of the female mouse of the ovariectomized female mouse, and shows that both RG3 and nilestriol can obviously increase the bone mineral content of the ovariectomized female mouse.

Experimental example 220 (R) -ginsenoside Rg3 Experimental study on osteoporosis effect

1 materials of the experiment

1.1 drugs and reagents

20(R) -ginsenoside Rg3 (content > 98%), produced by Dalian Fusheng Natural drug development Co., Ltd, batch number: 2012303, respectively; using the ginsenoside Rg3 standard substance provided by Chinese medicine biological product verification for reference and performing HPLC calibration, wherein the content is 98.2%;

positive control drug: nilestriol tablets are manufactured by Beijing tetracyclic pharmaceuticals, Inc., national drug Standard Hl1020123, lmg/tablet, 10 tablets/box.

Retinoic acid tablets, produced by Shandong Liafu pharmaceutical Co., Ltd, are in Chinese medicine standard H20083494, 10 mg/tablet and 20 tablets/box.

Estradiol (E2) quantitative determination kit (chemiluminescence method) xiamenbosheng biotechnology limited.

Osteocalcin (BGP) detection kit shanghai valley research industries, ltd.

Human Calcitonin (CT) enzyme-linked immunoassay kit Shanghai Langton Biotechnology Ltd.

Insulin-like growth factor-receptor I/II (IGF-I/IIR) ELISA kits Shanghai Jianglai Biotech Ltd.

1.2 Experimental animals

Wistar rats, 50, half male and female, weight 180 g-220, 3 months old, purchased from the university of Dalian medical laboratory animal center, quality certification number: SCXK (13) 2012-.

2 method of experiment

2.1 animal model creation

The rats are adaptively fed for 3 days, 10 rats are randomly selected as normal control groups, and the rest 40 rats are molded, each is treated by pressing

Feeding tretinoin 75mg/kg. d for 15d, and intragastrically irrigating the control group with distilled water of the same amount.

2.2 animal groups

30 adult mice were randomly divided into a model group, an RG3 group, a nilestriol-treated control group, and a normal group, to give 4 groups, each of which was 10 mice.

2.3 methods of treatment

After the model is successfully made and divided into groups, the rats in each group begin to be treated by intragastric administration according to the lml/100g dose, and the rats in the normal group are: 0.9% normal saline is drenched; model group: 0.9% normal saline is drenched; rg3 group: drench 6mg/1kg body weight rg 3; the four groups of rats were gavaged once a day, and the control group: neestriol is administrated by drenching, and is mixed with normal saline to obtain suspension with concentration of 0.2mg/m1 before use, and the lml/100g is drenched once per week without restriction on food intake and water intake, and the period is 8 weeks.

2.4 Observation index and index detection method

Serological examination of rats: after the experiment is finished, each group of rats respectively adopt eyeball picking to draw blood, centrifugally separate serum, store the serum in a refrigerator at the temperature of 20 ℃ below zero, and respectively measure the following indexes of the serum of the rats by applying a radioimmunoassay method: estradiol (E2), osteocalcin (BGP), Calcitonin (CT), insulin-like growth factor-I (IGI-I), all following strictly kit instructions.

3 results of the experiment

3.1 Effect of RG3 on rat serum E2

The results of the measurement of estradiol (E2) in rat serum are shown in Table 2.

TABLE 2 Effect of RG3 on rat serum E2 (x. + -. s)

Group of	Number of examples	E2(ng/L)
			Normal control group	10	49.13±3.42
Model control group	10	4.28±0.89*
			RG3 group	10	31.07±3.16*△□
Positive drug control group	10	23.25±2.84*△

Note P <0.01 compared to normal group, △ P <0.01 compared to model group, □ P <0.01 compared to nilestriol group.

The experimental results of table 1 show that: after 8 weeks of administration, the serum estradiol content of rats in a normal control group is the highest, the animal estradiol content can be obviously increased after the administration of the RG3 group, and compared with a model group, the animal estradiol content has significant difference (P <0.01) and is obviously superior to that of the control group (P <0.01), which shows that the RG3 can obviously increase the estradiol content of experimental animals.

3.2 Effect of RG3 on the Effect of rat serum osteocalcin (BGP)

The results of the measurement of osteocalcin (BGP) in rat serum are shown in Table 3.

TABLE 3 Effect of RG3 on rat serum osteocalcin (BGP) (x. + -.s)

As can be seen from table 3: after the drug treatment, the serum osteocalcin levels of rats are compared, the model control group and the normal control group have very significant difference (P <0.01), and the RG3 treatment group has significant difference (P <0.01) compared with the model group and the positive drug (nilestriol) group.

3.3 Effect of RG3 on the Effect of rat serum Calcitonin (CT)

The results of Calcitonin (CT) assay in rat serum are shown in Table 4.

TABLE 4 Effect of RG3 on rat CT (x. + -. s)

From the measurement results in table 4, it is clear that: the serum calcitonin of the two treatment groups and the normal control group is higher than that of the model group (P <0.01), and the RG3 group has obvious effect (P <0.01) compared with the positive medicament (nilestriol) group, and the experiment shows that the RG3 can obviously improve the serum calcitonin level of the osteoporosis rat.

3.4 Effect of RG3 on the Effect of rat serum IGI-I (insulin-like growth factor-I)

The results of the measurement of IGI-I (insulin-like growth factor-I) in rat serum are shown in Table 5.

TABLE 5 Effect of RG3 on rat IGI-I (x. + -. s)

Note P <0.01 compared to normal, model △ P <0.01, □ compared to Neestriol P < 0.01.

As can be seen from table 5: after 8 weeks of administration, the normal control group rats have the highest content of IGI-I in serum, the RG3 group can obviously increase the content of the IGI-I in animals after administration, and compared with the model group, the RG3 group has significant difference (P <0.01) and is obviously superior to the control group (P <0.01) after 8 weeks of administration, which shows that the RG3 can obviously increase the content of the IGI-I in experimental animals.

Claims

1.20 application of (R) -ginsenoside Rg3 as the only active component in preparing drugs or health products for treating osteoporosis.

2. The use as claimed in claim 1, wherein the medicament consists of 20(R) -ginsenoside Rg3 and a pharmaceutically acceptable carrier.

3. Use according to claim 1 or 2, characterized in that the medicament is in the form of tablets, capsules, pills, powders, granules, syrups, solutions, emulsions, injections, sprays, aerosols, gels, creams, tinctures or patches.

4. Use according to claim 1 or 2, characterized in that the medicament is in the form of a cataplasm or a rubber patch.

5. The use according to claim 1 or 2, wherein the content of 20(R) -ginsenoside Rg3 is not less than 98%.

6. A medicine or health care product for treating osteoporosis is characterized by comprising the following raw materials in proportion:

dissolving ginsenoside Rg3 with small amount of ethanol, adding Saviae Miltiorrhizae radix extract, semen Sesami Niger extract and glucose syrup, and adding deionized water to 1000 ml.

7. The medicine or health care product as claimed in claim 6, wherein the content of the 20(R) -ginsenoside Rg3 is more than or equal to 98%.